Pfizer’s updated COVID-19 booster significantly revved up adults’ virus-fighting antibodies, the company said Friday, releasing early findings from a rigorous study of the new shots.
Opinions expressed by Forbes Contributors are their own. I am a writer, journalist, professor, systems modeler, computational and digital health expert, avocado-eater, and entrepreneur, not always ...
According to Pfizer/BioNTech, preclinical data has shown that a booster dose with the BA.4/BA.5-adapted bivalent vaccine generated a strong neutralising antibody response against Omicron BA.1, BA ...
In contrast to the initial belief that long COVID symptoms were associated with the direct viral damage caused by SARS-CoV-2, studies now point to a systemic pathophysiology affecting multiple ...
You will be able to book an appointment via the NHS App, the NHS website, by calling 119, or by visiting a drop-in clinic.
Moderna's patent lawsuit claiming Pfizer and BioNTech copied its COVID-19 vaccine technology will be put on hold while the ...
Though COVID-19 cases are currently low, nearly 2,300 people have died in Florida this year after catching the virus ...
Future of Healthcategory BioNTech wins up to $90 mln in funding for mpox vaccine development September 18, 2023 Healthcare & Pharmaceuticalscategory US FDA authorizes Pfizer-BioNTech and Moderna's ...
OTTAWA - Health Canada has authorized Pfizer-BioNTech's updated COVID-19 vaccine for people six months and older. The mRNA vaccine targets the Omicron XBB.1.5 subvariant that is circulating in Canada.
Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024 Conference call and webcast scheduled for ...
Seamless reading experience. Save your favourite. The drugmaker received a $28 million grant from the Bill and Melinda Gates Foundation in September to support the launch of the respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback